Parkinson’s Disease PBMC

In Stock Samples

Lot # Condition Cell Count (M) Race/Ethnicity Age Gender Country of Collection Medications Vials Price Action
78360 Parkinson's Disease 10M 71 Male Ukraine
Acetylsalicylic acid, Carbidopa/levodopa
1
78361 Parkinson's Disease 10M 71 Male Ukraine
Acetylsalicylic acid, Carbidopa/levodopa
1
78362 Parkinson's Disease 10M 71 Male Ukraine
Acetylsalicylic acid, Carbidopa/levodopa
1
78363 Parkinson's Disease 10M 71 Male Ukraine
Acetylsalicylic acid, Carbidopa/levodopa
1
78377 Parkinson's Disease 10M 74 Female Ukraine
Acetylsalicylic acid, Bisoprolol, Carbidopa/levodopa
1
78378 Parkinson's Disease 10M 74 Female Ukraine
Acetylsalicylic acid, Bisoprolol, Carbidopa/levodopa
1
78379 Parkinson's Disease 10M 74 Female Ukraine
Acetylsalicylic acid, Bisoprolol, Carbidopa/levodopa
1
78380 Parkinson's Disease 10M 74 Female Ukraine
Acetylsalicylic acid, Bisoprolol, Carbidopa/levodopa
1
78429 Parkinson's Disease 10M 72 Male Ukraine
Acetylsalicylic acid, Bisoprolol, Carbidopa/levodopa
1
78430 Parkinson's Disease 10M 72 Male Ukraine
Acetylsalicylic acid, Bisoprolol, Carbidopa/levodopa
1

Parkinson’s Disease PBMC for Neurodegeneration and Peripheral Immunology Research

Parkinson’s Disease Human PBMC products are sourced from IRB-consented donors clinically diagnosed with Parkinson’s disease, processed within 24 hours of collection and cryopreserved in CryoStor CS10. These peripheral blood mononuclear cells support genetic, transcriptomic and cellular immunology work in a neurodegenerative disease.

Parkinson’s Disease Biology and Why PBMC

Parkinson’s disease is a neurodegenerative disorder, not an autoimmune disease. Its defining pathology is progressive loss of dopaminergic neurons in the substantia nigra together with intracellular alpha-synuclein aggregation.

  • Alpha-synuclein misfolding and aggregation into Lewy pathology is the central molecular event, and peripheral cells are used to study handling of alpha-synuclein and related proteostasis machinery
  • Loss of nigrostriatal dopaminergic neurons produces the motor phenotype and underlies dopaminergic pharmacotherapy
  • Common genetic risk variants in LRRK2 and GBA1 are among the best established in the field, and PBMC provide accessible genomic DNA and matched living cells from carriers
  • Mitochondrial and lysosomal-autophagy pathway dysfunction, including PINK1 and PRKN biology, is measurable in peripheral mononuclear cells
  • Peripheral immune involvement is an active research area rather than a settled mechanism: altered monocyte and T cell phenotypes have been reported in Parkinson’s cohorts, and this is the main scientific justification for a PBMC product
  • PBMC also support iPSC reprogramming for patient-derived neuronal models, plus flow cytometry, single-cell RNA sequencing and ex vivo functional assays

Donor Stratification Available

  • Disease stage by clinician assessment, where recorded
  • Disease duration since diagnosis
  • Genetic status where available, including LRRK2 and GBA1 variant carriers
  • Treatment status: levodopa-treated, dopamine agonist-treated, or treatment-naive
  • Motor phenotype, including tremor-dominant versus postural instability and gait difficulty
  • Presence or absence of documented cognitive involvement
  • Matched healthy controls available, age- and sex-matched on request

Product Features

  • Research Use Only (RUO), cryopreserved PBMCs
  • Clinically confirmed Parkinson’s disease donors
  • Available in cell counts ranging from 5 million to 2 billion
  • Processed within 24 hours of collection
  • Stored using CryoStor® CS10 freezing media
  • IRB-approved protocols and electronic informed consent
  • Screen LeukoLot™ available prior to bulk orders

De-identified Donor Data

  • Verified Parkinson’s disease diagnosis
  • Donor demographics: age, sex assigned at birth, race/ethnicity
  • Self-reported allergies and infectious disease history
  • Medication history, including dopaminergic therapy
  • Additional Parkinson’s disease-specific data available upon request

Applications

  • Peripheral immune cell phenotyping in neurodegeneration
  • Single-cell and bulk transcriptomic profiling
  • Genomic DNA extraction for LRRK2, GBA1 and polygenic risk genotyping
  • Mitochondrial function and mitophagy assays in primary human cells
  • Lysosomal and autophagy pathway research, including glucocerebrosidase activity
  • iPSC reprogramming and patient-derived neuronal model generation
  • Target validation and compound screening for disease-modifying candidates
  • Biomarker discovery against age- and sex-matched healthy controls

Other Parkinson’s Disease Specimen Types

Compliance and Quality Assurance

  • IRB-approved collections and protocols
  • 21 CFR Part 11 – compliant e-consent system
  • HIPAA-compliant donor data protection

Ordering & Customization

Parkinson’s Disease PBMC samples are shipped on dry ice and available in custom aliquots. For pricing, availability, international orders or regulatory requirements, please contact learnmore@sanguinebio.com to confirm documentation and compliance needs. To browse PBMC from other disease states and check live stock status, visit our human PBMC page.

Protocols & Documentation

  • PBMC Isolation from Whole Blood

    Standard operating procedure for isolating peripheral blood mononuclear cells from whole blood using density-gradient separation.

    Download
  • Immune Cell Isolation

    Guidelines for isolating immune cell populations with validated enrichment steps, purity checkpoints, and documentation.

    Download
  • Choosing the Right PBMC Configuration

    Reference guide comparing PBMC formats, cryopreservation states, and study-fit recommendations for your application.

    Download
  • Thawing Cryopreserved PBMC

    Validated thawing protocol to recover viable cryopreserved PBMCs while minimizing activation and loss of function.

    Download
  • Informed Consent Form (ICF)

    Available upon request — confirms donor consent for research use and downstream commercialization.

PBMC

Frequently Asked Questions

Showing 1–12 of 30 results

Are samples IRB approved?

1 Answer

YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.

YES – all our products are research use only (RUO).

Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.

Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.

Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.

Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.

YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.

Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.

YES – Unique donors can be specified and guaranteed based on your requirements.

For information about sample quality, please see: Quality and Compliance

YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.

1
×

Ask a Question

Need a custom PBMC cohort?

Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.

More Information